tafasitamab
Showing 1 - 25 of 38
Mantle Cell Lymphoma Trial in Miami, Houston (Zanubrutinib, Tafasitamab)
Not yet recruiting
- Mantle Cell Lymphoma
- Zanubrutinib
- Tafasitamab
-
Miami, Florida
- +1 more
Aug 31, 2023
Tafasitamab in Combination With Lenalidomide in Patients withR/R
Not yet recruiting
- Diffuse Large B-cell Lymphoma
- Tafasitamab Injection
-
Shanghai, ChinaRuijin Hospital, Shanghai Jiao Tong University School of Medicin
May 31, 2023
Non-Hodgkin Lymphoma Trial in Cologne (Tafasitamab, Lenalidomide, Rituximab)
Not yet recruiting
- Non-Hodgkin Lymphoma
- Tafasitamab
- +3 more
-
Cologne, GermanyUniversity of Cologne
Oct 14, 2022
Hodgkin Lymphoma, B-Cell Lymphoma, Relapsed B-cell NHL Trial in Houston (Mosunetuzumab, Polatuzumab vedotin, Tafasitamab)
Not yet recruiting
- Hodgkin Lymphoma
- +2 more
- Mosunetuzumab
- +3 more
-
Houston, TexasM D Anderson Cancer Center
Nov 7, 2022
Chronic Lymphocytic Leukemia Trial in Portland (drug, procedure, biological, other)
Not yet recruiting
- Chronic Lymphocytic Leukemia
- Acalabrutinib
- +8 more
-
Portland, OregonOHSU Knight Cancer Institute
Jul 12, 2023
DLBCL Trial in San Juan (PF-07901801, Tafasitamab, Lenalidomide)
Not yet recruiting
- Diffuse Large B-Cell Lymphoma
- PF-07901801
- +2 more
-
San Juan, Puerto RicoAuxilio Mutuo Cancer Center
Jan 19, 2023
CNS Lymphoma, Primary CNS Lymphoma, Secondary CNS Lymphoma Trial in San Francisco (Tafasitamab, Lenalidomide)
Recruiting
- CNS Lymphoma
- +2 more
- Tafasitamab
- Lenalidomide
-
San Francisco, CaliforniaUniversity of California, San Francisco
Aug 10, 2022
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma Trial in Duarte (procedure, biological, drug)
Not yet recruiting
- Chronic Lymphocytic Leukemia
- Small Lymphocytic Lymphoma
- Biospecimen Collection
- +4 more
-
Duarte, CaliforniaCity of Hope Medical Center
Jan 30, 2023
ALL, Childhood B-Cell, Acute Lymphoid Leukemia Relapse, Acute Lymphocytic Leukemia Refractory Trial (Tafasitamab)
Not yet recruiting
- ALL, Childhood B-Cell
- +2 more
- Tafasitamab
- (no location specified)
Nov 25, 2022
DLBCL Trial in Hangzhou (Tafasitamab and Lenalidomide)
Recruiting
- DLBCL
- Tafasitamab and Lenalidomide
-
Hangzhou, Zhejiang, ChinaThe First Afflicated Hospital, College of Medicine, Zhejiang Uni
Sep 21, 2022
Diffuse Large-cell B-cell Lymphoma Trial in Seattle (plamotamab, tafasitamab, lenalidomide)
Recruiting
- Diffuse Large-cell B-cell Lymphoma
- plamotamab
- +2 more
-
Seattle, WashingtonSwedish Cancer Center
May 2, 2022
Mantle Cell Lymphoma, MCL Trial in United States (Tafasitamab, Lenalidomide)
Recruiting
- Mantle Cell Lymphoma
- MCL
- Tafasitamab
- Lenalidomide
-
Basking Ridge, New Jersey
- +6 more
Mar 27, 2023
Recurrent Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma Trial in Rochester (procedure, drug, biological)
Not yet recruiting
- Recurrent Mantle Cell Lymphoma
- Refractory Mantle Cell Lymphoma
- Biopsy
- +10 more
-
Rochester, MinnesotaMayo Clinic in Rochester
Jun 9, 2023
Large B-Cell Lymphoma, DLBCL Trial (Tafasitamab, Lenalidomide)
Not yet recruiting
- Large B-Cell Lymphoma
- Diffuse Large B-Cell Lymphoma
- Tafasitamab
- Lenalidomide
- (no location specified)
Jun 17, 2022
Non Hodgkins Lymphoma, Diffuse Large B-cell Lymphoma Trial in Japan (tafasitamab, lenalidomide, parsaclisib)
Recruiting
- Non Hodgkins Lymphoma
- Diffuse Large B-cell Lymphoma
- tafasitamab
- +3 more
-
Aichi, Japan
- +4 more
Jan 24, 2022
Monomorphic B-Cell Post-Transplant Lymphoproliferative Disorder, Polymorphic Post-Transplant Lymphoproliferative Disorder Trial
Not yet recruiting
- Monomorphic B-Cell Post-Transplant Lymphoproliferative Disorder
- Polymorphic Post-Transplant Lymphoproliferative Disorder
- Biopsy
- +5 more
-
New Brunswick, New Jersey
- +2 more
Mar 23, 2023
Recurrent B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between DLBCL and Classic Hodgkin Lymphoma, Recurrent
Not yet recruiting
- Recurrent B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classic Hodgkin Lymphoma
- +21 more
- Biopsy
- +8 more
-
Columbus, OhioOhio State University Comprehensive Cancer Center
Apr 7, 2023
Grade 3b Follicular Lymphoma, High Grade B-Cell Lymphoma, High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6
Not yet recruiting
- Grade 3b Follicular Lymphoma
- +5 more
- Biospecimen Collection
- +9 more
- (no location specified)
Jun 6, 2023
DLBCL, Grade 3b Follicular Lymphoma, High Grade B-Cell Lymphoma Trial in Seattle (procedure, drug, biological)
Not yet recruiting
- Diffuse Large B-Cell Lymphoma
- +2 more
- Biopsy
- +7 more
-
Seattle, WashingtonFred Hutch/University of Washington Cancer Consortium
Jul 12, 2022
DLBCL Trial in Belgium, France (Tafasitamab, Lenalidomide, Rituximab)
Recruiting
- DLBCL
- Tafasitamab
- +2 more
-
Brussels, Belgium
- +14 more
Mar 3, 2022
Diffuse Large B Cell Lymphoma Trial in Worldwide (Tafasitamab, Lenalidomide)
Recruiting
- Diffuse Large B Cell Lymphoma
- Tafasitamab
- Lenalidomide
-
Dallas, Texas
- +29 more
Jan 20, 2023
B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative Trial in Seattle (procedure, drug, biological)
Not yet recruiting
- B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative
- Bone Marrow Aspiration and Biopsy
- +7 more
-
Seattle, WashingtonFred Hutch/University of Washington Cancer Consortium
Jul 11, 2022
DLBCL Trial in Houston (Acalabrutinib, Cyclophosphamide, Doxorubicin Hydrochloride)
Recruiting
- Diffuse Large B-Cell Lymphoma
- Acalabrutinib
- +7 more
-
Houston, TexasM D Anderson Cancer Center
Jul 10, 2022
Chronic GVHD, Hematologic and Lymphocytic Disorder, Steroid Refractory GVHD Trial in Duarte (procedure, biological, other)
Not yet recruiting
- Chronic Graft Versus Host Disease
- +2 more
- Biopsy
- +11 more
-
Duarte, CaliforniaCity of Hope Medical Center
Aug 7, 2023